Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cabiralizumab - Bristol-Myers Squibb/Five Prime Therapeutics

Drug Profile

Cabiralizumab - Bristol-Myers Squibb/Five Prime Therapeutics

Alternative Names: BMS-986227; Cabiralizumab; FPA-008; ONO-4687

Latest Information Update: 24 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Five Prime Therapeutics
  • Developer Bristol-Myers Squibb; Five Prime Therapeutics; NYU Langone Health; Pyxis Oncology; University of Chicago; University of Michigan Rogel Cancer Center; Yale University
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Macrophage colony stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pigmented villonodular synovitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Liver cancer; Pancreatic cancer; Peripheral T-cell lymphoma; Pigmented villonodular synovitis
  • Phase I/II Triple negative breast cancer
  • No development reported Cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 23 Aug 2023 Apexigen has been acquired and merged into Pyxis Oncology
  • 06 Jul 2023 University of Michigan Rogel Cancer Center in collaboration with Bristol-Myers Squibb completes a phase II trial in Peripheral T-cell lymphoma (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT03927105)
  • 01 Jun 2023 Bristol-Myers Squibb completes a phase-II trial in Pancreatic cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in Canada, Denmark, Germany, Japan, Italy, Spain, Switzerland, South Korea, Taiwan, USA and United Kingdom (IV) (NCT03336216; EudraCT2018-000339-28)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top